GEH has changed tack, the ESBWR is on the backburner, they will be using a modified version of the ABWR or two newer versions which are on the drawing board right now, they are called RMWR, and RBWR, they are the LWR version to burn used nuclear fuel, the other generation four reactor they also have is called PRISM.
The Reduced-Moderation Water Reactor (RMWR) is a light water reactor, essentially as used today, with the fuel packed in more tightly to reduce the moderating effect of the water. Considering the BWR variant (resource-renewable BWR - RBWR), only the fuel assemblies and control rods are different. In particular, the fuel assemblies are much shorter, so that they can still be cooled adequately. Ideally they are hexagonal, with Y-shaped control rods. The reduced moderation means that more fissile plutonium is produced and the breeding ratio is around 1 (instead of about 0.6), and much more of the U-238 is converted to Pu-239 and then burned than in a conventional reactor. Burn-up is about 45 GWd/t, with a long cycle. Initial seed (and possibly all) MOX fuel needs to have about 10% Pu. The void reactivity is negative, as in conventional LWR. A Hitachi RBWR design based on the ABWR-II has the central part of each fuel assembly (about 80% of it) with MOX fuel rods and the periphery uranium oxide. In the MOX part, minor actinides are burned as well as recycled plutonium.
The main rationale for RMWRs is extending the world's uranium resource and providing a bridge to widespread use of fast neutron reactors. Recycled plutonium should be used preferentially in RMWRs rather than as MOX in conventional LWRs, and multiple recycling of plutonium is possible. Japan Atomic Energy Research Institute (JAERI) started the research on RMWRs in 1997 and then collaborated in the conceptual design study with the Japan Atomic Power Company (JAPCO) in 1998. Hitachi has also been closely involved, with its RBWR concept which has a major aim of burning actinides.
Not sure where you get your info from b1g_brothr?
You certainly need to brush up on your research.
Google some of this before shooting your mouth off,
"Advances in laser enrichment may enable relatively low-cost plutonium isotopic separation creating a new unexplored dimension in fuel cycle options."
"Hitachi developing reactor that burns nuclear waste"
"Technical Evaluation of the Hitachi Resource-Renewable BWR (RBWR) Design Concept"
"Hitachi collaborates on TRU-consuming reactor development"
They didn't shut the shop up, they are just working on an additional method for more power from used nuclear fuel, GLE will be getting Uranium from the tails at Paducah, they will also be getting for next to nothing enriched Uranium from used nuclear fuel and now you can add to that Plutonium with 240Pu removed, they will now have U235 and Pu239 as a new MOX fuel, one that is very very cheap and can be burnt in GEH's ABWR and a newer version of that coming called the SBWR, they dropped the baton on the ESBWR for this so it must be bloody good?
If any of that comes off? There will be little need fro enriched Uranium well into the forseeable future!
Sentiment: Strong Sell
That is no problem for LIS technology, but I believe they can just separate out the U235 leaving everything else behind, you can't do this with centrifuge technology.
Google this "report to Congress: Advanced Reactor Licensing August 2012" now look at the figure Figure 5.1, called Potential Future Reactor Licensing on or around page 61, you will notice in that PDF figure 5.1 that generation III LWR's stop being licensed around in around 10 years according to the NRC predictions, they also predict that generation IV reactors (Liquid Metal Reactors) like PRISM will start being licensed around 2018-19.
GEH has a plan for PRISM reactors that will have an Advanced Recycling Center located on exactly the same site as the PRISM which it itself is co located with an existing LWR and uses all of the existing used nuclear fuel at that site. in that ARC they intend to separate out Plutonium and also the remaining Uranium which is called RepU, to be able to use this RepU they will either have to re enrich the recovered uranium (U235() to a higher degree or separate or only the U235 away from the other actinides, some of which counter the effects of the U235 they are basically a nuclear poison to it. if GEH can do this and I believe they can? then I would suggest that LEU will be in a very precarious position because centrifuge technology cannot do this Isotope Separation effectively, because if this technology of the ARC which is an electro chemical process to separate the Plutonium from the Uranium and they either use laser enrichment or laser Separation (LIS) the latter which I believe is the proffered method, then there will be all the Lightly Enriched Uranium available from the used nuclear fuel to supply the whole of the US for a very long time, same goes for the rest of the world, there will not be any need for the supply of natural Uranium or for the enrichment of that Uranium to LEU, GEH will get this LEU for next to nothing, so I can't see Centrus being a competitor somehow?
I say this as a heads up, I genuinely feel sorry for you people here hanging on in hope.
google this S-PRISM Fuel Cycle Study For Session 3: Future Deploym
Another arm chair expert, someone who knows next to nothing about the company.
Of course phase one ,two and three are important, but one of the earlier drugs from exactly the same tree that Novogen first developed was quite successful in phase one and two, but failed in phase three simply because the management back then in their wisdom decided to change the delivery method to oral at the last hurdle (really bad idea) it was called Phenoxodiol.
The drugs Novogen now have are 1000 times stronger than those older drugs, this is why Yale's Dr Gil Mor, didn't cut and run when the phase three failed back then, they have followed the drugs Novogen has for a very long time now and actually own 15% of one of the drugs, CanTX they are bringing to trials, Yale will get 2% royalty from that collaboration, Yale also stated that they have NEVER seen aside from the drug that Novogen has, a drug by any other drug company, capable of killing both cancer and also stem cell cancers, aside from what Novogen has, but there are also other collaborations they have, one with Weil Cornell Medical School for the development of a drug to treat Glioblastoma for the treatment of Brain Cancer, they also have another collaboration with Genea Biocells to develop Stem cell therapy in a new and novel development to help with the growth of brain stem cells, as well as developing other drugs to treat Degenerative diseases like Parkinson's disease Altzimers and a number of other degenerative illnesses.
So in your esteemed opinion, are all of those collaborations with highly respected organizations just a waste of time?